SECTOR GAMMA AS
SEC Form 13F institutional filer · CIK 0001475373
13F-HR · 23 reported holdings · 2026-03-31
Reported long-US-equity value
$0.32B
Top-10 concentration
71.7%
SECTOR GAMMA AS — $319M AUM allocation strategy
SECTOR GAMMA AS files SEC Form 13F and reports $319M of long US equity value across 23 reported holdings for 2026-03-31.
Its largest sector bet is Health Care 94.8%, followed by Financials 1.5%.
The top 10 holdings account for 72% of reported value — a conviction-weighted book concentrated in its best ideas. The sector and industry splits below are of the same reported value. Track quarter-over-quarter adds, trims, new positions and exits below — sourced from SEC 13F filings, public domain.
SECTOR GAMMA AS — latest SEC 13F insights
Reported long-US-equity value (13F AUM)
$319M
total across 23 reported holdings · 2026-03-31 · excludes shorts, cash, non-US
Top-10 concentration
72% of value
higher = narrower conviction; lower = spread / hedging
Biggest adds (shares)
+$PFE +232K sh · +$9.24M+$BMY +81.9K sh · +$9.98M+$ZBH +23.4K sh · +$2.18M
Biggest trims (shares)
−$GILD −123K sh · −$14.2M−$MRK −103K sh · −$6.96M−$CNC −95.7K sh · −$5.3M
Exited to nil (held last quarter, gone now)
$TMO ($12.6M last qtr)$REGN ($5.53M last qtr)$HCA ($5.03M last qtr)
Sector allocation (share of reported value)
each slice is a share of the reported long-US-equity value — smaller sectors and the rest of the book roll into “Other holdings”
Qtr shift = share-point change vs the prior quarter's filing — first period tracked for this filer; the column fills in with the next quarterly refresh.
Industry allocation (share of reported value)
- Pharmaceuticals35.2%—
- Health Care Equipment21.8%—
- Biotechnology18.6%—
- Managed Health Care8.8%—
- Health Care Services4.6%—
- Health Care Distributors3.7%—
- Life Sciences Tools & Services2.1%—
- Asset Management & Custody Banks1.5%—
- Other holdings3.8%—
the finer GICS cut of the same book — same denominator — smaller industries roll into “Other holdings”
Qtr shift = share-point change vs the prior quarter's filing — first period tracked for this filer; the column fills in with the next quarterly refresh.
Top S&P 500 holdings
10 of 10 rows · sorted by Value ↓
| Ticker | Holding | Shares | Value | Δ QoQ | Weight |
|---|---|---|---|---|---|
| $BMY | Bristol-Myers Squibb Company | 828K | $50.2M | +81.9K | 15.7% |
| $MRK | Merck & Company Inc | 260K | $31.3M | -103K | 9.8% |
| $PFE | Pfizer Inc | 1.09M | $30.6M | +232K | 9.6% |
| $MDT | Medtronic plc | 281K | $24.3M | +11K | 7.6% |
| $INCY | Incyte Corp | 201K | $18.9M | -18.3K | 5.9% |
| $AMGN | Amgen Inc | 47.2K | $16.6M | -13.8K | 5.2% |
| $BIIB | Biogen Inc | 90.1K | $16.5M | +4.62K | 5.2% |
| $ZBH | Zimmer Biomet Holdings Inc | 156K | $14.1M | +23.4K | 4.4% |
| $BDX | Becton Dickinson and Company | 82.6K | $13M | -49.8K | 4.1% |
| $ELV | Elevance Health Inc | 44K | $12.9M | +11.4K | 4.0% |
…and 13 more holdings in the full 13F filing (top positions only shown).
SEC Form 13F data sets · public domain · 45-day filing lag · >$100M AUM managers · as reported
← All 13F filers·← QuantOrb.pro
How to read Δ QoQ — the five insight categories, and the caveats
The categories. Analysts, quants and retail traders look past total portfolio value to isolate actionable signals. Five categories matter.
Conviction & concentration shifts
New positions vs complete exits — a brand-new stock signals high conviction; a full liquidation suggests a broken thesis or tax-loss harvesting. Aggressive sizing — look at share count, not dollars: a 20% share increase during a drawdown is strong dip-buying. Concentration — a narrowing top-5/10 means conviction; spreading capital across more names means hedging.
Sector & macro allocation rotations
Aggregating Δ QoQ moves across sectors shows where smart money is leaning in or sneaking out — rotating out of growth into defensives or energy, for example. The fund's total long equity exposure quarter-over-quarter is a proxy for overall institutional risk appetite.
Crowding & smart-money consensus
When several managers initiate or expand the same stock in the same quarter, that is institutional consensus. Contrarian reads: top pickers buying hard into a beaten-down name the market is selling.
Derivative & option overlays
Reported call/put changes indicate whether managers are adding downside hedges or leveraging upside exposure. Note: a long increase may be half of a market-neutral pair trade.
Who reads this
| Retail "cloners" | High-conviction ideas to replicate ~45 days after quarter-end. |
| Corporate IR | Which funds bought or dumped the stock, before the next call. |
| Quant / algo traders | Cross-sectional factor inputs: flow, momentum, ownership. |
Four caveats before you trade on it
- 45-day lag — holdings are quarter-end; positions may already be closed.
- Long-only — 13Fs miss shorts, pair trades and cash.
- No non-US / fixed income — the picture is US equities plus options.
- Corporate actions — splits and spinoffs distort raw share deltas.
Newsletter signup
Free subscription. Daily trading day morning dispatch. No spam.